The Cost-Effectiveness Analysis of Anaprazole Versus Ilaprazole for Treating Duodenal Ulcers in China

Background


- Anaprazole is a innovative drug developed in China for the treatment of pep tic ulcer disease, which has shown promising results in initial clinical trials.
- It has the potential to become a new treatment option and may reduce the fina \bullet ncial burden on patients compared to imported proton pump inhibitors.

Objectives

• To evaluate the economic efficacy of Anaprazole compared to Ilaprazole enteric coated tablets (Ilaprazole) in the treatment of duodenal ulcers (DU).

Methods

- From the perspective of the **health system**, this study utilized **two multicente** r randomized controlled trial (RCT) as data sources.
- We will compare the **efficacy** and **safety** of **Anaprazole** and **Ilaprazole** using anchored indirect matching-adjusted comparison (MAIC).
- **Cost-utility analysis (CUA)** was conducted to assess the **economic value** of t he two drugs based on a Markov model.
- To test the uncertainty in the model, deterministic sensitivity analysis (DS) A) and probability sensitivity analysis (PSA) were performed.



Huitong Ni¹, Jiagi Shi¹, Haoning Zhu¹, Ming Hu¹, Shu Yang^{1*}, Naitong Zhou^{1*} 1 West China School of Pharmacy, Sichuan University, Chengdu, China

Recovery

Results

- Anaprazole and Ilaprazole are equally effective in treating DU (OR = 1.05; **95% CI, 0.94-1.01; P=0.35**).
- There was no significant difference in the incidence of **adverse drug reaction** s (ADRs) between Ilaprazole and Anaprazole (OR = 0.63; 95% CI, 0.39-1. **08; P=0.12**).
- The CUA results show that the ICUR value is 2995.41 ¥/QALY, which is lo wer than willingness to pay (WTP).
- **DSA** showed that the two most sensitive factors to the model were the drug c ost of Anaprazole and Ilaprazole, respectively; **PSA** shows that when the **W TP** value is **85698.00** \mathbf{Y} , the probability of **Anaprazole** being more cost effe ctive than **Ilaprazole** is **85%**.

MAIC

(a) Forest plot of effectiveness Lable OR (95%CI) Before Adjusting: Anaprazole vs. Rabeprazole 1.49 (0.73, 3.02) After Adjusting: Anaprazole vs. Rabeprazole 1.61 (0.72, 3.59) llaprazole vs. Rabeprazole 1.68 (0.91, 3.10) Before Adjusting: Anaprazole vs. llaprazole 2.63 (2.61, 2.65) After Adjusting: Anaprazole vs. llaprazole 1.05 (0.94, 1.05)

(b)


Forest plot of safety

Lable	OR (95%
 Before Adjusting: Anaprazole vs. Rabeprazole	1.49 (0.73,
After Adjusting: Anaprazole vs. Rabeprazole	1.61 (0.72,
llaprazole vs. Rabeprazole	1.68 (0.91,
Before Adjusting: Anaprazole vs. llaprazole	2.63 (2.61,
 After Adjusting: Anaprazole vs. llaprazole	1.05 (0.94,


CUA


Cost-utility analysis result							
Group	Cases	cost	Utility	C/U	ICUR		
		(C, ¥)	(U, QALY)	(¥/QALY)	(¥/QALY)		
Anaprazole	179	5423.6137	0.9803	5532.8304	2005 4000		
Ilaprazole	129	5421.1818	0.9794	5534.9337	2995.4090		





Sensitivity analysis





Presented at ISPOR 2024, ay 5-8,2024, Atlanta, GA, USA

EE177

Date: Monday, May 6, 2024 Poster Session Time: 3:30 PM - 6:30 PM